Study of transplant preparation for older adults with AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special preparation (conditioning) regimen for patients 55 or older with acute myeloid leukemia (AML) who are in first remission and receiving a half-matched (haploidentical) stem cell transplant. It aims to make the transplant safer and more effective for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years old or older.
- You have been diagnosed with acute myeloid leukemia (AML) and are in your first complete remission (meaning the leukemia is not active right now).
- You have a half-matched (haploidentical) donor available, such as a parent, child, or sibling.
- This would be your first stem cell transplant.
- You do not have a fully matched sibling or unrelated donor available.
- You are willing to give written permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.